{"filing":{"accession_number":"0001213900-26-104314","cik":"0001766140","ticker":"UNCY","company_name":"Unicycive Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-28","primary_document":"ea0306967-8k_unicycive.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026104314/ea0306967-8k_unicycive.htm"},"events":[{"id":35599,"run_id":32797,"accession_number":"0001213900-26-104314","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Meredith S. Manning was appointed as an independent director effective October 1, 2026, with assignment as Chairperson of the Nominating and Corporate Governance Committee, bringing extensive biopharmaceutical leadership and commercial expertise.","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39704,"accession_number":"0001213900-26-104314","item_number":"5.02","item_title":"Departure","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Meredith S. Manning as an independent director effective October 1, 2026, with committee assignments including Chairperson of the Nominating and Corporate Governance Committee. This is a clear executive/board appointment under Item 5.02, driven by her extensive biopharmaceutical leadership experience and commercial expertise relevant to the company's regulatory and commercial trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:47:41.144023+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":35600,"run_id":32797,"accession_number":"0001213900-26-104314","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Unicycive announced the resubmission of a New Drug Application (NDA) for oxylanthanum carbonate with a new manufacturing vendor and updated CMC data, directly addressing prior FDA deficiencies and positioning the company for potential approval within 6 months of FDA acceptance.","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39705,"accession_number":"0001213900-26-104314","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Unicycive announced the resubmission of a New Drug Application (NDA) for oxylanthanum carbonate with a new manufacturing vendor and updated CMC data. This is a material regulatory milestone for a clinical-stage biotech company—the resubmission directly addresses prior FDA deficiencies and positions the company for potential approval within 6 months of FDA acceptance. While this is a significant operational/regulatory event, it does not fit neatly into the specific event-type categories (not an earnings release, M\u0026A activity, impairment, litigation, or other named types), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:47:41.144023+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39704,"accession_number":"0001213900-26-104314","item_number":"5.02","item_title":"Departure","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Meredith S. Manning as an independent director effective October 1, 2026, with committee assignments including Chairperson of the Nominating and Corporate Governance Committee. This is a clear executive/board appointment under Item 5.02, driven by her extensive biopharmaceutical leadership experience and commercial expertise relevant to the company's regulatory and commercial trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:47:41.144023+00:00","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-09-29"},{"id":39705,"accession_number":"0001213900-26-104314","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Unicycive announced the resubmission of a New Drug Application (NDA) for oxylanthanum carbonate with a new manufacturing vendor and updated CMC data. This is a material regulatory milestone for a clinical-stage biotech company—the resubmission directly addresses prior FDA deficiencies and positions the company for potential approval within 6 months of FDA acceptance. While this is a significant operational/regulatory event, it does not fit neatly into the specific event-type categories (not an earnings release, M\u0026A activity, impairment, litigation, or other named types), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:47:41.144023+00:00","company_name":"Unicycive Therapeutics, Inc.","ticker":"UNCY","filing_date":"2026-09-29"}]}